The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma

被引：0
|
作者：
Rose, April A. N. [1 ]
Armstrong, Susan M. [1 ]
Hogg, David [2 ]
Butler, Marcus [2 ]
Joshua, Anthony M. [3 ]
Ghazarian, Danny [4 ]
Kamel-Reid, Suzanne [4 ]
Al Habeeb, Ayman [4 ]
Chappell, Mary Anne [2 ]
Ross, Kendra [2 ]
Amir, Eitan [2 ]
Bedard, Phillippe L. [2 ]
Siu, Lillian [2 ]
Spreafico, Anna [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Kinghorn Canc Ctr, Sydney, NSW, Australia
[4] Univ Hlth Network, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-3141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3141
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Dantoing, Edouard
    Piton, Nicolas
    Salaun, Mathieu
    Thiberville, Luc
    Guisier, Florian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [22] Association between TERT promoter mutations and BRAF/NRAS mutations in patients with primary and metastatic melanoma tumors
    Chang, Gregory A.
    Tadepalli, Jyothirmayee S.
    Fleming, Nathaniel H.
    Lui, Kevin
    Shao, Yongzhao
    Darvishian, Farbod
    Pavlick, Anna
    Berman, Russell
    Shapiro, Richard
    Osman, Iman
    Polsky, David
    CANCER RESEARCH, 2015, 75
  • [23] Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma
    Roncati, Luca
    ACTA DERMATOVENEROLOGICA CROATICA, 2018, 26 (04) : 341 - 343
  • [24] Flow cytometric analysis of immune responses in the melanoma tissue biopsies before or during anti-PD1 immunotherapy
    Shklovskaya, Elena
    Lee, Jenny
    Lim, Su Yin
    Alavi, Sara
    Thompson, John
    Saw, Robyn
    Carlino, Matteo
    Scolyer, Richard
    Menzies, Alexander
    Long, Georgina
    Kefford, Richard
    Rizos, Helen
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [25] Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors.
    Barcena, Edelyn
    VanAnh Trinh
    McIntyre, Susan E.
    Simien, Rinata
    Cain, Suzanne
    Diab, Adi
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Tawbi, Hussein Abdul-Hassan
    Davies, Michael A.
    Hwu, Wen-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.
    Zimmer, Lisa
    Dimitriou, Florentia
    Grover, Piyush
    Hassel, Jessica Cecile
    Erdmann, Michael
    Forschner, Andrea
    Johnson, Douglas Buckner
    Livingstone, Elisabeth
    Roesch, Alexander
    Ugurel, Selma
    Schulz, Carsten
    Berking, Carola
    Menzies, Alexander M.
    Long, Georgina V.
    Dummer, Reinhard
    Schadendorf, Dirk
    Albrecht, Lea Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
    Pires da Silva, Ines
    Zakria, Danny
    Ahmed, Tasnia
    Trojanello, Claudia
    Dimitriou, Florentia
    Allayous, Clara
    Gerard, Camille
    Zimmer, Lisa
    Lo, Serigne
    Michielin, Olivier
    Lebbe, Celeste
    Mangana, Johanna
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Carlino, Matteo
    Menzies, Alexander
    Long, Georgina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [28] Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
    da Silva, I. Pires
    Zakria, D.
    Ahmed, T.
    Trojaniello, C.
    Dimitriou, F.
    Allayous, C.
    Gerard, C.
    Zimmer, L.
    Lo, S.
    Michielin, O. A.
    Lebbe, C.
    Mangana, J.
    Ascierto, P. A.
    Johnson, D.
    Carlino, M.
    Menzies, A. M.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S873 - S874
  • [29] Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
    Tsao, H
    Goel, V
    Wu, H
    Yang, G
    Haluska, FG
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (02) : 337 - 341
  • [30] Home anti-PD1 immunotherapy for melanoma: results of a patient and nursing satisfaction survey
    Truong, Thu Thao
    Lapassat, Marie
    Belbezier, Aude
    Leccia, Marie-Therese
    Mouret, Stephane
    Lemoigne, Aude
    Charles, Julie
    Trabelsi, Sabiha
    EUROPEAN JOURNAL OF DERMATOLOGY, 2025, 35 (01) : 31 - 37
12345